

# Philip Seo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8825571/publications.pdf>

Version: 2024-02-01

120  
papers

9,428  
citations

53660

45  
h-index

39575

94  
g-index

122  
all docs

122  
docs citations

122  
times ranked

6099  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypothyroidism in vasculitis. <i>Rheumatology</i> , 2022, 61, 2942-2950.	0.9	2
2	Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA-Associated Vasculitis. <i>ACR Open Rheumatology</i> , 2022, 4, 168-176.	0.9	6
3	SARS-CoV-2 Vaccine Response in Patients With Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Kidney International Reports</i> , 2022, 7, 629-632.	0.4	5
4	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	0.6	2
5	Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	12
6	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. <i>American Journal of Human Genetics</i> , 2021, 108, 84-99.	2.6	26
7	Factors Affecting Dilation Interval in Patients With Granulomatosis With Polyangiitis-Associated Subglottic and Glottic Stenosis. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 165, 019459982110042.	1.1	6
8	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	0.9	21
9	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2021, 73, 1088-1105.	1.5	90
10	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1366-1383.	2.9	249
11	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1349-1365.	2.9	231
12	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis Care and Research</i> , 2021, 73, 1071-1087.	1.5	61
13	Correspondence on SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response by Bonelli <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e164-e164.	0.5	17
14	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. <i>Kidney International Reports</i> , 2021, 6, 2903-2907.	0.4	8
15	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. <i>JCI Insight</i> , 2021, 6, .	2.3	7
16	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 114-118.	0.4	3
17	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 114-118.	0.4	14
18	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 283-291.	0.4	40

#	ARTICLE	IF	CITATIONS
19	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020, 59, 1118-1127.	0.9	33
20	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1001-1010.	1.0	20
21	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	1.5	77
22	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. <i>Frontiers in Immunology</i> , 2020, 11, 2053.	2.2	12
23	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 576-581.	1.6	25
24	Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. <i>JCI Insight</i> , 2020, 5, .	2.3	6
25	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 707-713.	1.6	43
26	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Autoimmunity</i> , 2019, 105, 102302.	3.0	24
27	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2203-2211.	0.9	37
28	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1888-1893.	2.9	25
29	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1879-1887.	2.9	23
30	053. CLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
31	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 322-328.	0.9	28
32	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1114-1121.	2.9	49
33	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. <i>Rheumatology</i> , 2018, 57, 639-650.	0.9	20
34	The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 251-257.	2.2	50
35	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018, 13, e0205768.	1.1	6
36	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Kidney International Reports</i> , 2018, 3, 1039-1049.	0.4	41

#	ARTICLE	IF	CITATIONS
37	Long-term Clinical Course of Antineutrophil Cytoplasmic Antibody-associated Vasculitis Patients off Maintenance Therapy. <i>Cureus</i> , 2018, 10, e2372.	0.2	5
38	Pauci-immune Glomerulonephritis in Systemic Lupus Erythematosus (SLE). <i>Cureus</i> , 2018, 10, e2949.	0.2	3
39	A Randomized, Double-blind Trial of Abatacept (CTLA4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 846-853.	2.9	131
40	A Randomized, Double-blind Trial of Abatacept (CTLA4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 837-845.	2.9	271
41	ANCA-Associated Vasculitis Pathogenesis: A Commentary. <i>Current Rheumatology Reports</i> , 2017, 19, 15.	2.1	19
42	Macular lymphocytic arteritis: Clinical-pathologic correlation of a rare vasculitis. <i>JAAD Case Reports</i> , 2017, 3, 116-120.	0.4	4
43	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78
44	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. <i>American Journal of Nephrology</i> , 2017, 46, 231-238.	1.4	15
45	The Pharmacogenomic Association of Fcγ3 Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 169-175.	2.9	21
46	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 1004-1010.	1.5	11
47	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-associated Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 185-193.	2.9	45
48	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 98-101.	0.4	3
49	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. <i>Analytical Chemistry</i> , 2016, 88, 6317-6325.	3.2	24
50	Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. <i>International Journal of Cardiology</i> , 2016, 217, 135-148.	0.8	114
51	The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2016, 43, 1078-1084.	1.0	37
52	Eosinophilic Granulomatosis with Polyangiitis: Challenges and Opportunities. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 520-521.	2.0	1
53	Myeloperoxidase-associated Antineutrophil Cytoplasmic Antibody (ANCA)-positive and ANCA-negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. <i>Arthritis and Rheumatology</i> , 2016, 68, 2945-2952.	2.9	75
54	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. <i>Arthritis and Rheumatology</i> , 2016, 68, 1700-1710.	2.9	132

#	ARTICLE	IF	CITATIONS
55	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1166-1169.	0.5	196
56	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	1.6	109
57	Rituximab for treatment of severe renal disease in ANCA associated vasculitis. <i>Journal of Nephrology</i> , 2016, 29, 195-201.	0.9	33
58	Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). <i>PLoS ONE</i> , 2015, 10, e0121737.	1.1	35
59	Identification of Susceptibility Loci in <i>IL6</i> , <i>RPS9</i> / <i>LILRB3</i> , and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1361-1368.	2.9	79
60	Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 1213-1217.	1.0	129
61	Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1922-1932.	2.9	116
62	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015, 42, 1209-1212.	1.0	87
63	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	2.6	144
64	Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study. <i>BMC Nephrology</i> , 2015, 16, 88.	0.8	13
65	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 976-985.	3.0	137
66	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2015, 54, 1351-1359.	0.9	52
67	Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 535-544.	2.9	25
68	Current Status of Outcome Measure Development in Vasculitis. <i>Journal of Rheumatology</i> , 2014, 41, 593-598.	1.0	31
69	An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1376-1379.	0.5	128
70	Otolaryngological Progression of Granulomatosis with Polyangiitis after Systemic Treatment with Rituximab. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 150, 68-72.	1.1	11
71	Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 778-783.	1.6	9
72	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2013, 369, 417-427.	13.9	611

#	ARTICLE	IF	CITATIONS
73	Vasculitis in the intensive care unit. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 95-106.	1.4	13
74	Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. <i>American Journal of Human Genetics</i> , 2013, 93, 298-305.	2.6	143
75	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1342-1350.	0.5	109
76	Association of Granulomatosis With Polyangiitis (Wegener's) With <i>HLA-DPB1*04</i> and <i>SEMA6A</i> Gene Variants: Evidence From Genome-Wide Analysis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2457-2468.	6.7	138
77	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2013, 40, 1905-1912.	1.0	40
78	Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2013, 40, 674-683.	1.0	39
79	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1329-1334.	0.5	218
80	Association of Vascular Physical Examination Findings and Arteriographic Lesions in Large Vessel Vasculitis. <i>Journal of Rheumatology</i> , 2012, 39, 303-309.	1.0	51
81	Persistent or New Onset Microscopic Hematuria in Patients with Small Vessel Vasculitis in Remission: Findings on Renal Biopsy. <i>Journal of Rheumatology</i> , 2012, 39, 1413-1417.	1.0	27
82	Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3463-3471.	6.7	33
83	Advances in Therapy for ANCA-Associated Vasculitis. <i>Current Rheumatology Reports</i> , 2012, 14, 509-515.	2.1	7
84	Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis. <i>PLoS ONE</i> , 2012, 7, e30197.	1.1	16
85	Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2012, 64, 273-279.	1.5	49
86	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 80-85.	0.5	47
87	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multicenter Experience. <i>Transplantation</i> , 2011, 91, 1370-1375.	0.5	71
88	Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis. <i>Current Immunology Reviews</i> , 2011, 7, 423-428.	1.2	0
89	The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis. <i>Journal of Rheumatology</i> , 2011, 38, 1480-1486.	1.0	105
90	Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda. <i>Journal of Rheumatology</i> , 2011, 38, 1471-1479.	1.0	79

#	ARTICLE	IF	CITATIONS
91	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis Care and Research</i> , 2011, 63, 588-596.	1.5	147
92	Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): Long-term followup of a multicenter longitudinal cohort. <i>Arthritis and Rheumatism</i> , 2011, 63, 2495-2503.	6.7	58
93	Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3988-3997.	6.7	59
94	Biologic agents in systemic vasculitis. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 453-462.	0.3	3
95	Life-Threatening Presentations of ANCA-Associated Vasculitis. , 2011, , 101-117.		0
96	Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. <i>Arthritis Care and Research</i> , 2010, 62, 1639-1645.	1.5	86
97	Alpha <sub>1</sub> -antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2010, 62, 3760-3767.	6.7	87
98	Renal Transplant in Wegener's Granulomatosis Compared to Microscopic Polyangiitis. <i>Journal of Rheumatology</i> , 2010, 37, 1705-1708.	1.0	9
99	Microscopic Polyangiitis. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 545-558.	0.8	106
100	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2010, 363, 221-232.	13.9	2,275
101	Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9. <i>Journal of Rheumatology</i> , 2009, 36, 2362-2368.	1.0	35
102	Assessment of damage in vasculitis: expert ratings of damage. <i>Rheumatology</i> , 2009, 48, 823-827.	0.9	34
103	Vasculitis: lessons learned. <i>Current Opinion in Rheumatology</i> , 2009, 21, 1-2.	2.0	4
104	Advances in the use of biologic agents for the treatment of systemic vasculitis. <i>Current Opinion in Rheumatology</i> , 2009, 21, 3-9.	2.0	31
105	Development of comprehensive disease assessment in systemic vasculitis. <i>Postgraduate Medical Journal</i> , 2008, 84, 143-152.	0.9	91
106	Wegener's granulomatosis: managing more than inflammation. <i>Current Opinion in Rheumatology</i> , 2008, 20, 10-16.	2.0	26
107	Vasculitides. , 2008, , 427-434.		1
108	Polyarteritis Nodosa: The Great Mimicker, Mimicked. <i>Southern Medical Journal</i> , 2008, 101, 351-352.	0.3	1

#	ARTICLE	IF	CITATIONS
109	Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. <i>Journal of Rheumatology</i> , 2008, 35, 2017-23.	1.0	78
110	Pregnancy and Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 299-317.	0.8	38
111	Small-vessel and medium-vessel vasculitis. <i>Arthritis and Rheumatism</i> , 2007, 57, 1552-1559.	6.7	23
112	The future of damage assessment in vasculitis. <i>Journal of Rheumatology</i> , 2007, 34, 1357-71.	1.0	33
113	Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). <i>Arthritis and Rheumatism</i> , 2005, 52, 2168-2178.	6.7	171
114	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. <i>Journal of Rheumatology</i> , 2005, 32, 2488-95.	1.0	32
115	Large-vessel vasculitis. <i>Arthritis and Rheumatism</i> , 2004, 51, 128-139.	6.7	85
116	The antineutrophil cytoplasmic antibody-associated vasculitides. <i>American Journal of Medicine</i> , 2004, 117, 39-50.	0.6	459
117	Cases from the Osler Medical Service at Johns Hopkins University. <i>American Journal of Medicine</i> , 2002, 112, 667-669.	0.6	0
118	Cases from the medical grand rounds of the osler medical service at Johns Hopkins University. <i>American Journal of Medicine</i> , 2002, 112, 730-732.	0.6	4
119	Cases from the Osler Medical Service at Johns Hopkins University. <i>American Journal of Medicine</i> , 2002, 113, 522-524.	0.6	3
120	Expression of the sea urchin MyoD homologue, SUM1, is not restricted to the myogenic lineage during embryogenesis. <i>Mechanisms of Development</i> , 1999, 86, 209-212.	1.7	10